6564 Results

People

  1. Gonen
    Gonen
  2. Panageas
    Panageas
  3. Patil
    Patil
  4. Giralt
    Giralt
  5. Zhang
    Zhang
  6. Heller
    Heller
  7. Devlin
    Devlin
  8. Seshan
    Seshan
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Biostatistics Service (6564)
  2. Epidemiology and Biostatistics (6564)
  3. Department of Medicine (3848)
  4. Solid Tumor Oncology Division (2571)
  5. Survivorship Research (2487)
  6. Surgery (2392)
  7. Population Sciences Research Program (2339)
  8. Center for Pancreatic Cancer Research (2080)
  9. GSK Faculty (1977)
  10. Department of Pathology and Laboratory Medicine (1573)
  1. "Biostatistics Service"
Formats
  1. Journal Article (3978)
  2. Meeting Abstract (2394)
  3. Research Letter (51)
  4. Conference Paper (37)
  5. Correspondence (26)
  6. Editorial (25)
  7. Review (21)
  8. Miscellaneous (14)
  9. Book Section (13)
  10. Book Whole (3)
  11. Guidelines (2)
Groups
  1. Biostatistics Service (6564)
  2. Epidemiology and Biostatistics (6564)
  3. Department of Medicine (3848)
  4. Solid Tumor Oncology Division (2571)
  5. Survivorship Research (2487)
  6. Surgery (2392)

More Groups

People
  1. Mithat Gonen (1028)
  2. Sean Devlin (601)
  3. Katherine Panageas (512)
  4. Sujata Patil (511)
  5. Sergio Giralt (464)
  6. Zhigang Zhang (427)

More People

Years
  1. 2025 (118)
  2. 2024 (362)
  3. 2023 (411)
  4. 2022 (407)
  5. 2021 (369)
  6. 2020 (394)

More Years

Publications
  1. Journal of Clinical Oncology (1058)
  2. Blood (432)
  3. Annals of Surgical Oncology (308)
  4. International Journal of Radiation Oncology, Biology, Physics (233)
  5. Clinical Cancer Research (195)
  6. Biology of Blood and Marrow Transplantation (174)

More Publications

Publishers
  1. American Society of Clinical Oncology (1124)
  2. Elsevier Inc. (930)
  3. Springer (625)
  4. American Society of Hematology (486)
  5. American Association for Cancer Research (430)
  6. Nature Publishing Group (311)

More Publishers

Results (6564)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of romiplostim on overall survival in chemotherapy induced thrombocytopenia
    Meeting Abstract

    Wilkins, C. R.; Zwicker, J. I.; Derkach, A.; Burge, M.
    Blood (2023)

    Fulltext@MSK | Save
  • Despite high rates of remission, treatment of IDH-mutant AML with hypomethylating agents and venetoclax is associated with frequent treatment delays, modifications, and transfusions
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Berman, E.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Rampal, R. K.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TNC/Kg and CD34+/Kg cell dose impact on patient engraftment after allogeneic transplant with conventional bone marrow; Better predictability of graft content needed
    Meeting Abstract

    Davis, E.; Feuer, E.; Rapoport, C.; Lobaugh, S.; Devlin, S. M.; Archer, A.; Chinapen, S.; Federman, J.; Kelly, A.; Klein, E.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • An inflammatory biomarker signature reproducibly predicts CAR-T treatment failure in patients with aggressive lymphoma across the ZUMA trials cohorts
    Meeting Abstract

    Raj, S.; Xie, J.; Fei, T.; Song, Q.; Kim, J. J.; To, C.; van den Brink, M. R. M.; Perales, M. A.; Mattie, M.; Shouval, R.
    Blood (2023)

    Fulltext@MSK | Save
  • A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy
    Meeting Abstract

    Nath, K.; Shekarkhand, T.; Costa, B. A.; Nemirovsky, D.; Derkach, A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D.; Landau, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A. D.; Salles, G.; Yahalom, J.; Imber, B. S.
    Blood (2023)

    Fulltext@MSK | Save